Neurocrine Biosciences (NBIX) Tops Q3 EPS by 29c, Beats on Revenue; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $146.10 -0.19%
Revenue Growth %: +30.8%
Financial Fact:
General and administrative: 17.49M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: +30.8%
Financial Fact:
General and administrative: 17.49M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $1.81, $0.29 better than the analyst estimate of $1.52. Revenue for the quarter came in at $622.1 million versus the consensus estimate of $600.97 million.
GUIDANCE:
Neurocrine Biosciences sees FY2024 revenue of $2.3-2.32 billion, versus the consensus of $2.33 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- University Bancorp acquires remaining 20% of UIF for $15.2M
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
